Food And Drug Administration Center For Biologics Evaluation And Research Vaccines And Related Biological Products Advisory Committee N

Vaccines And Related Biological Products Advisory Committee Meeting March 15, 2005

Holiday Inn Select, 8120 Wisconsin Ave., Bethesda, MD 20814

DRAFT AGENDA

8:30 a.m. 8:35	Call to Order Administrative Matters	Gary Overturf, M.D., Chair Christine Walsh R.N., FDA	
Session 1 – Open Committee Discussion – Safety and Immunogenicity for Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap) manufactured by GlaxoSmithKline Biologicals			
8:45	Tdap Introduction/Background/ Presentation of Questions	Theresa Finn, Ph.D., FDA	
9:00	Clarifications/Questions		
9:05	GSK/Tdap/Boostrix	GlaxoSmithKline	
10:05	Clarifications/Questions		
10:15	Break		
10:30	FDA Presentation	Ann Schwartz, M.D., FDA	
11:00	Clarifications/Questions		
11:10	Open Public Hearing		
11:40	Committee Discussion and Recommendations		
12:40 p.m.	Lunch		
Session II – Open Committee Discussion – Safety and Immunogenicity data for Tdap vaccine manufactured by Aventis Pasteur Ltd			
1:45	Adacel Introduction	Martha Monser, B.A., FDA	
1:55	AP Tdap/Adacel	Aventis Pasteur, Ltd.	
2:55	Clarifications/Questions		

Food And Drug Administration Center For Biologics Evaluation And Research Vaccines And Related Biological Products Advisory Committee Meeting March 15, 2005

Holiday Inn Select, 8120 Wisconsin Ave., Bethesda, MD 20814

DRAFT AGENDA

3:05	Break	
3:20	FDA Presentation	Chris Mink, M.D., FDA
4:00	Clarifications/Questions	
4:10	Open Public Hearing	
4:40	Committee Discussion and Recommendation	
5:40	Adjourn Meeting	